CytomX Therapeutics, Inc. (CTMX) Cash and securities
- Total cash · latest quarter (USD): Value $330.28M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $330.28M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $17.22M + $313.06M ≈ $330.28M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 17.22M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 313.06M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Cash and current securities | 330.28M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $330.28M | (m) | $17.22M | $313.06M | (m) |
| 2026-03-31 | $346.71M | (m) | $28.83M | $317.88M | (m) |
| 2025-12-31 | $137.05M | (m) | $12.67M | $124.39M | (m) |
| 2025-09-30 | $143.63M | (m) | $34.19M | $109.44M | (m) |
| 2025-06-30 | $158.09M | (m) | $49.04M | $109.05M | (m) |
| 2025-03-31 | $79.89M | (m) | $47.60M | $32.28M | (m) |
| 2024-12-31 | $100.62M | (m) | $38.05M | $62.57M | (m) |
| 2024-09-30 | $117.59M | (m) | $40.58M | $77.01M | (m) |
| 2024-06-30 | $137.18M | (m) | $43.25M | $93.94M | (m) |
| 2024-03-31 | $150.28M | (m) | $36.19M | $114.10M | (m) |
| 2023-12-31 | $174.51M | (m) | $17.17M | $157.34M | (m) |
| 2023-09-30 | $194.11M | (m) | $26.02M | $168.09M | (m) |
| 2023-06-30 | $180.86M | (m) | $57.54M | $123.32M | (m) |
| 2023-03-31 | $204.50M | (m) | $56.36M | $148.15M | (m) |
| 2022-12-31 | $193.65M | (m) | $193.65M | $0.00 | (m) |
| 2022-09-30 | $194.29M | (m) | $95.04M | $99.25M | (m) |
| 2022-06-30 | $228.16M | (m) | $129.29M | $98.88M | (m) |
| 2022-03-31 | $262.53M | (m) | $163.49M | $99.04M | (m) |
| 2021-12-31 | $305.23M | (m) | $205.53M | $99.70M | (m) |
| 2021-09-30 | $236.29M | (m) | $236.28M | $5.00K | (m) |
| 2021-06-30 | $266.18M | (m) | $256.15M | $10.03M | (m) |
| 2021-03-31 | $393.80M | (m) | $329.67M | $64.13M | (m) |
| 2020-12-31 | $316.12M | (m) | $191.86M | $124.26M | (m) |
| 2020-09-30 | $321.08M | (m) | $176.81M | $144.27M | (m) |
| 2020-06-30 | $346.40M | (m) | $291.39M | $55.01M | (m) |
| 2020-03-31 | $247.92M | (m) | $143.29M | $104.64M | (m) |
| 2019-12-31 | $296.14M | (m) | $188.43M | $107.72M | (m) |
| 2019-09-30 | $325.71M | (m) | $164.65M | $161.07M | (m) |
| 2019-06-30 | $349.14M | (m) | $149.39M | $199.75M | (m) |
| 2019-03-31 | $396.60M | (m) | $190.41M | $206.19M | (m) |
| 2018-12-31 | $436.13M | (m) | $247.58M | $188.55M | (m) |
| 2018-09-30 | $464.56M | (m) | $259.75M | $204.81M | (m) |
| 2018-06-30 | $335.15M | (m) | $132.91M | $202.24M | (m) |
| 2018-03-31 | $361.48M | (m) | $142.16M | $219.32M | (m) |
| 2017-12-31 | $374.11M | (m) | $177.55M | $196.56M | (m) |
| 2017-09-30 | $331.27M | (m) | $284.23M | $47.05M | (m) |
| 2017-06-30 | $335.92M | (m) | $272.86M | $63.06M | (m) |
| 2017-03-31 | $162.52M | (m) | $85.66M | $76.86M | (m) |
| 2016-12-31 | $181.94M | (m) | $104.64M | $77.29M | (m) |
| 2016-09-30 | $178.47M | (m) | $59.76M | $118.71M | (m) |
| 2016-06-30 | $195.80M | (m) | $62.38M | $133.42M | (m) |
| 2016-03-31 | $180.64M | (m) | $67.90M | $112.74M | (m) |
| 2015-12-31 | $186.71M | (m) | $59.82M | $126.89M | (m) |
| 2015-09-30 | (m) | (m) | $36.19M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $45.84M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $7.82M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $64.40M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $53.31M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $8.70M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $14.75M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |